LBRX (LBRX) reported R&D of $14.65M in Q1 2026.

How has LBRX's R&D changed year-over-year?

LBRX's R&D increased by 328.1% year-over-year, from $3.42M to $14.65M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

LBRX LBRX R&D

R&D at other companies

Bristol-Myers SquibbBMY

$2.65B+17.4%

AlkermesALKS

$103.35M+43.9%

MapLight Therapeutics, Inc. MPLT

$53.68M+171%

Alto NeuroscienceANRO

$20.29M+103%

Zevra Therapeutics, Inc.ZVRA

$4.39M+34.8%

Opko HealthOPK

$29.2M-5.3%

Other financials

Income statement

See full

Net income-$19.1M-259%

EPS (diluted)-$0.67+95.5%

Balance sheet

See full

Cash & equivalents$320.7M—

Total debt$3.5M—

Total equity$378.7M+481%

Total assets$393.5M—

Cash flow

See full

Operating cash flow-$23.3M-187%

CapEx$32.0K+52.4%

Free cash flow-$23.3M-186%

Valuation

See full

Market cap$874.06M+163%

Enterprise value$556.86M—

Returns & leverage

See full

Return on equity-27.9%—

Debt / equity0×—

Current ratio35.7×—

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is LBRX's R&D?: LBRX (LBRX) reported R&D of $14.65M in Q1 2026.
How has LBRX's R&D changed year-over-year?: LBRX's R&D increased by 328.1% year-over-year, from $3.42M to $14.65M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.